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STUDY DESIGN: Explanatory and mechanistic study.
OBJECTIVES: A better understanding of the ‘whole-body’ response following spinal cord injury (SCI) is needed to guide future
research aimed at developing novel therapeutic interventions and identifying prognostic indicators for SCI. This study aimed to
characterise the blood proteome following contusion or complete SCI compared to a sham injury in rat models.
SETTING: United Kingdom.
METHODS: Pooled blood samples from one and seven days after a contusion (serum; n= 5) or from 14 days and 112 days post-
complete transection SCI (plasma; n= 8) and their sham-injured counterparts were subjected to independent iTRAQ nanoflow
liquid chromatography tandem mass-spectrometry proteomic analyses. Pathway analyses of the proteins that were differentially
abundant between SCI and their matched sham injured counterparts were completed to indicate biological pathways that may be
changed in response to SCI.
RESULTS: Eleven and 42 proteins were differentially abundant (≥±2.0 FC; p ≤ 0.05) between the contusion SCI and sham injured
animals at 24 h and seven days post-injury, respectively. Seven and tweleve proteins were differentially abundant between
complete and sham injured rats at 14 and 112 days post-injury, respectively. Acute-phase response signalling and Liver X Receptor/
Retinoic X Receptor activation were identified as differentially regulated pathways in both models of SCI.
CONCLUSIONS: We have utilised longitudinal preclinical SCI models to provide an insight into the blood proteome changes that
result following SCI and to highlight a number of biological pathways of interest for future studies.
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INTRODUCTION
Many clinical and scientific attempts have been made to better
diagnose and to develop new treatments to improve the
prognosis of individuals following a spinal cord injury (SCI). There
is growing evidence that measures of some haematological
indices post-injury relate with longer term (12 month) clinical
outcome measures in human SCI patients [1, 2]. These studies
indicate that over-time the ‘whole-body’, multi-organ response to
SCI contributes to long-term clinical outcome and that proteins
within the blood can be used to assess this phenomenon [1, 2].
Therefore a better understanding of the longitudinal protein
changes within the blood following a SCI is needed to develop
novel interventions [3].
The majority of studies that have aimed to understand protein
changes that occur following a SCI, have focused upon changes
within the SC tissue itself [3]. We have previously reviewed the few
studies that have assessed the protein response to SCI in either
the blood or cerebrospinal fluid (CSF) of SCI animal models or
humans with a SCI [3]. It is particularly desirable to identify
markers that can be measured systemically as blood samples can
be collected immediately after injury with fewer associated risks
compared to CSF samples. Having a better understanding of the
proteome response to SCI in blood, will aid in the development of
novel inteventions for SCI, as well as to identify candidate
biomarkers that may have the potential to better determine SCI
severity or predict clinical outcome of human with a SCI [4].
Several well-characterised pre-clinical SCI models exist which
aim to represent the different common human SCI situations,
contusive (blunt force) or penetrative (stab) injuries. In animals
contusion injuries are commonly modelled using specialised
devices that deliver an impact of calibrated force to the surgically
exposed spinal cord [5, 6]. Penetrative injury, in humans more
commonly leads to complete SCI, in which a variable cross section
of the spinal cord is transected [7]. Surgical exposure and
complete incision across all SC tracts is commonly performed in
these animal models using either microscissors or a scalpel blade
under visual control [8]. Rodent models are invaluable in studying
the underlying mechanisms of SCI, as there is evidence that they
undergo similar biological processes to humans following injury
[9] and allow for comparison to sham injured animals (via surgical
exposure of, but no injury to, the SC) whereas such comparator
control groups are difficult to identify in the human situation.
Proteomics is a powerful analytical tool that can be used to
profile large numbers of proteins in an untargeted manner. We
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Table 1. Protein changes in rat blood following contusion spinal cord injury compared to sham injury at either 1 day or 7 days following injury.




FDR (p value) (a) 1 day SCI: 1 day
sham; (b) 7 day SCI: 7 day sham
Up in SCI Fibrinogen alpha chain isoform 1 FGA 8.3 10.5 (a) 0.0007; (b) 0.0005
Haemoglobin subunit alpha-1/2 HBA-1 8.3 3.8 (a) 0.0002; (b) 0.001
Beta-2-glycoprotein 1 APOH 3.5 0.03




Prealpha-2-macroglobulin A2M 10.8 0.03
Fibrinogen beta chain precursor FGB 7.9 0.02
Myosin-11 MYH-11 6.0 0.04
Fibrinogen gamma chain FGG 5.75 9.48 × 10−9
Serine protease inhibitor A3M Serpina3m 3.4 0.001
Antithrombin-III SERPINA1 2.6 0.0002
















Gelsolin GSN −3.4 0.0002
Complement C5 C5 −3.3 2.07E-08
C9 protein C9 −2.8 −8.5 (a) 0.0001; (b) 6.87E-05
Serum amyloid P-component APCS −2.5 0.002
Plasma kallikrein KLKB1 −2.4 0.005
Ab1-018 Ab1-018 −20.5 0.0003
C-reactive protein CRP −16.1 0.005
Alpha-1-acid glycoprotein ORM1 −13.7 0.01
Vitamin D-binding protein Gc −9.8 1.17E-09




Apolipoprotein E APOE −8.1 0.0002
Alpha-1-antiproteinase SERPINA1 −7.8 0.0004
Complement factor H CFH −7.5 1.77E-11
Complement component C6 C6 −6.3 6.26E-06
Fibronectin 1 FN1 −5.9 1.80E-07
Major urinary protein Mup −5.8 0.002
Complement C1S subcomponent C1s −5.8 0.0009
Plasma protease C1 inhibitor SERPING1 −5.5 0.0008
Clusterin Clu −4.9 0.009
Apolipoprotein C-I APOC1 −4.5 0.02
Apolipoprotein B-100 APOB −4.1 6.44 × 10−14 6
Fetub protein FETUB −3.5 0.001
Apolipoprotein A-I preproprotein Apoa1 −3.0 0.008
Angiotensinogen Agt −2.7 0.027
Afamin, isoform CRA_c Afm −2.6 9.02 × 10−8
Complement C4 C4 −2.3 0.004















have assessed the blood proteome of rat models of both a
contusion and a complete transection SCI to determine whether
we can detect differences between SC injured and sham injured
rodents. Consideration of the blood proteome in such pre-clinical
injury models could provide a more in-depth understanding of the
biochemical response to SCI compared to sham injury and how
these responses change over time in each independent model.
METHODS
Animals used in the study
All experimental procedures were approved by the Ethical Review Panel of
the University of Glasgow and carried out in accordance with the Animals
(Scientific Procedures) Act 1986 and adhering to our recommended good
practice for SCI rodent models [10]. Blood samples were collected surplus
to the study outcomes and were used in this study to maximise the output
from animal experiments in the spirit of the 3R’s of animal use
(replacement, refinement and reduction) [11]. Blood samples were
obtained at 1 day (n= 5) or 7 days (n= 5) after a contusion injury
performed at the C6 level [12] or at 14 days (n= 8) or 112 days (n= 8) after
a complete spinal cord transection performed at the T9 level [13]. Control
blood samples were obtained from animals that underwent sham surgery
performed at the same spinal level. Further details of the animal
experiments are included in the supplementary material (appendix 1).
Isobaric tag for relative and absolute quantitation proteomics
Two independent proteomic experiments were performed; one for the
contusion SCI (serum samples) and the other for the complete SCI (plasma
samples) models. Briefly, samples were pooled from the different injury
and timepoint groups, then prepared and analysed using isobaric tagging
for relative and absolute quantitation (iTRAQ) proteomics, as described
previously [14] and detailed in the supplementary material (Appendix 1).
Proteins which were differentially abundant between the SCI and matched
sham counterparts were selected where p < 0.05 and the fold change (FC)
was ≥±2.0.
Pathway analysis of proteomic datasets
Proteins were analysed using the pathway enrichment and topological
analysis tools in Ingenuity (Qiagen, US) [15] to identify and visualise the
canonical pathways which are differentially effected between SCI and sham
Table 1 continued




FDR (p value) (a) 1 day SCI: 1 day
sham; (b) 7 day SCI: 7 day sham
Lumican LUM −2.2 0.05




Vitamin K-dependent protein S PROS1 −2.0 0.002
FDR false discovery rate, SCI spinal cord injury.
Table 2. Protein changes in rat blood following complete spinal cord injury compared to sham injury at either 14 days or 112 days following injury.




FDR (P value)(a) 14 day SCI: 14 day
sham; (b) 112 day SCI:
112 day sham
Up after SCI 14-3-3 protein zeta/
delta
YWHAZ 14.5 0.03












Actin, cytoplasmic 2 ACTG1 −3.2 0.0001




Apolipoprotein A-IV APOA4 −2.6 8.1 × 10−6
Apolipoprotein B-100 APOB −2.1 0.001




Fibronectin FN1 −2.9 −4.1 (a) 1.3 × 10−7; (b) 6.2 × 10−11
Gelsolin GSN −2.3 0.04
Murinoglobulin-1 Mug1 −3 4.5 × 10−5
Murinoglobulin-2 Mug2 −1.7 0.0008
Vitamin D-binding
protein
GC −4.7 7.9 × 10−5
FDR false discovery rate, SCI spinal cord injury.
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injured rats at each of the timepoints of the study and in the different SCI
models. Functional annotations that were assigned a p value > 0.05, as
assessed using a Fisher’s exact test were removed from the list.
RESULTS
Differential abundance of proteins in the contusion versus
sham injured animals
All the proteins identified in the proteomic analysis of serum from
contusion SCI or sham counterparts are included in supplemen-
tary proteomic Table 1. Eleven proteins demonstrated ≥2.0 fold
differential abundance in the serum of contusion SC injured
compared to sham injured rats at one day post-injury (Table 1). At
seven days post-injury 42 proteins were differentially abundant
between contusion and sham injured rodents (Table 1). Three of
these proteins demonstrated common changes in abundance at
both timepoints; Fibrinogen alpha chain isoform 1 and haemo-
globin subunit alpha-1/2 had increased and C9 Protein had
decreased abundance across time i.e. at one day and seven days
post-injury (Table 1). Supplementary proteomic Table 2 and 3
detail all the proteins identified with ≥2 peptides and any ratio
between SCI and sham counterparts at 24 h and seven days post-
injury, respectively.
Differential abundance of proteins in the complete versus
sham injured animals
Supplementary proteomic table 5 details all the identified proteins
following iTRAQ proteomic analysis of plasma from the complete
SCI and sham counterpart animals. In serum collected at 14 days
post injury, a comparison of complete SC injured compared to
sham injured rats identified seven proteins that were differentially
abundant (±2.0 FC), three of which increased in abundance after
SCI (Table 2). Twelve serum proteins demonstrated a differential
abundance at 112 days after a SCI compared to sham injury, with
two proteins showing increased abundance and 10 showing
decreased abundance (Table 2). Supplementary proteomic tables 6
and 7 detail all the proteins identified with ≥2 peptides and any
ratio between SCI and sham counterparts at 14 days and 112 days
post-injury, respectively.
Biological functions associated with the protein changes
identified
In an aim to better interpret what the protein changes related to
in terms of biological function, pathway analysis was performed.
Biological pathways which had significant numbers of differen-
tially abundant proteins connected with them (determined by
Fisher’s exact test) could be identified.
Several functional pathways were associated with the protein
changes identified in the plasma of rats with a contusion SCI
compared to sham injured rats in the acute (1 day) phase of injury
(Fig. 1). The most significant functional pathways were: acute
phase response signalling (p= 1.1 × 10−13; predicted inhibition);
liver X receptor/retinoic X receptor (LXR/RXR) Activation (p= 1.8 ×
10−10); coagulation system (p= 9.6 × 10−9) and intrinsic pro-
thrombin activation pathway (p= 1.1 × 10−6). Several of these
pathways were still effected at a more sub-acute phase of injury
(7-days post-injury); namely, LXR/RXR activation (p= 6.0 × 10−17),
acute phase response signalling (p= 1.6 ×10−13) and the
coagulation system (p= 7.2 × 10−15). Other pathways, however,
were indicated as altered only at seven days post-injury, such as
the extrinsic prothrombin activation pathway (p= 5.9 × 10−12)
(Fig. 1).
Fig. 1 Heat map demonstrating canonical pathways that were most significantly enriched in spinal cord injured compared to sham
injured rats. The significance of the association of a given canonical pathway and the differentially abundant proteins was measured using
Fisher’s exact test. The heat map demonstrates the strength of the –log P value related to the Fisher’s exact test for each pathway in each
biological comparator group.
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The same analyses were performed based on the protein changes
detected within the serum of rodents with a complete SCI. Pathways
that were associated with protein changes seen at two weeks post-
injury included LXR/RXR activation (p= 3.5 × 10−12) and acute phase-
response signalling (p= 3.0 × 10−9), the complement system (p=
4.1 × 10−4) and Clatherin-mediated endocytosis signalling (p= 4.27 ×
10−4) (Fig. 1). Clatherin mediated endocytosis was also altered based
upon protein changes seen at 112 days following a complete injury
(p= 1.1 × 10−4), along with acute phase response signalling (p= 1.5 ×
10−8), the extrinsic prothrombin activation pathway (p= 3.0 × 10−5)
and the coagulation system (p= 1.5 × 10−4) (Fig. 1).
These biological pathways may provide targets for future work
aimed at targeting and/or developing therapies for SCI specific
responses. Furthermore, these analyses help to convey whether
specific biological functions are altered over time.
DISCUSSION
We have presented one of the first studies to assess how the
blood proteome changes after SCI in both contusive and complete
transection SCI models. This investigation has presented a unique
opportunity to determine the blood protein response to SCI in
order to greater understand the mechanisms underlying SCI and
repair.
One of the limitations of this study is that blood samples were
collected from animals at different timepoints following SCI and
different blood fractions were collected (plasma and serum).
Therefore, this study does not aim to directly compare between
the two different models but rather to demonstrate that following
SCI there are protein changes within the blood, which can be
detected in either blood fraction: serum or plasma. The range of
timepoints in these pre-clinical models has allowed for the blood
proteome to be assessed longitudinally, from the acute phase
(1 day post-contusion SCI) to the chronic phase (112 day post-
complete SCI) of injury. These proteomic analyses highlight that
there is a differential response to SCI compared to sham injury,
which can be detected in the blood in these rodent models over-
time.
Pathway analyses were used to provide a better understanding
of what the proteome changes might relate to in terms of
biological response to injury. These analyses allow for the
assessment of biological functional changes which present a
more global response within the blood. Therefore commonality in
functional pathway changes across time, irrespective of the blood
fraction and injury severity (contusion or complete) indicates that
these functional pathways are likely a specific response to SCI and
not sham injury and can be taken forward for further study with
much greater confidence. Moreover when the results from the
two rodent models are assessed independently, these novel
proteomic datasets present scientists with an understanding of
the systemic response to two widely used SCI models.
In the contusion model, only 11 proteins showed differential
abundance, based on our selection criteria, between the injured
and the sham injured animals at 24 h post-injury. This limited
number of alterations based on our fold change and p value cut-
offs, along with the large number of common proteins identified
in both the injured and sham sera, indicates that many of the
protein changes that do occur as an immediate response to injury
could be common to both SCI and sham injuries. Of the proteins
that were most highly differentially abundant in SCI compared
with sham injury at this acute timepoint, several were associated
with the haematological system and haemostasis e.g. fibrinogen
alpha chain isoform 1; haemoglobin subunit alpha 1/2; an
observation that is strengthened by our pathway analysis, which
also associated protein changes in this timeframe with the
coagulation system and the intrinsic prothrombin activation
pathway. These findings indicate that there is a response to SCI
which can be detected within the blood immediately after injury
and highlights the potential of assessing proteins which are not
associated with the SCI itself, e.g. neuronal or glial related protiens,
but rather that there may be a ‘whole-body’, multi-organ response
that is different in response to SCI compared with sham injury.
Interestingly, by seven days post-injury high numbers of
differentially abundant proteins were seen, many of which
displayed large FC differences in abundance, thus indicating that
there may be value in measuring blood proteins through the
acute phase of injury.
Studying the plasma proteome of rats following a complete
injury demonstrated that up to 112 days after injury protein
differences can be observed between SCI and sham injured
animals. These proteins can provide an insight into the potential
reparative and/or degenerative processes that continue long-
itudinally post-SCI. As with the contusion model, our pathway
analyses have highlighted that changes within the blood occur in
response to SCI, such as in the extrinsic prothrombin activation
pathway and the coagulation system, and this model highlights
that these may go on being implicated for a long period of time
following injury. We have previously demonstrated that red blood
cell (RBC) measures (RBCs, haematocrit and mean cell haemoglo-
bin) in the blood of humans with SCI at 7 ± 4 days post-SCI
correlate with initial AIS motor and sensory scores [1], confirming
that systemic release of red blood cell measures may be indicative
of injury severity.
Changes in acute phase response signalling were identified at
both the sub-acute (14 day) and chronic (112 day) timepoints
following complete injury and the acute (1 day) and sub-acute
(7 day) timepoints following contusion injury, highlighting that
changes in the acute phase response continue longitudinally post-
SCI. Acute phase response signalling is the first systemic response
to trauma [16], therefore it is unsurprising that in the case of SCI,
this signalling pathway is activated. This signalling cascade is
triggered by inflammatory cytokines which leads to drastically
changed protein synthesis by the liver and resultant release of the
acute phase proteins [16]. Therefore this signalling pathway
provides an attractive target for novel therapies, potentially by
targeting upstream inflammatory cytokines using biologic thera-
pies [17]. Changes in this pathway, along with identified changes
in LXR/RXR activation, add strength to our previous findings [1]
also highlighting the importance of considering the effect of SCI
on other organ systems aside from the nervous system, such as
the liver, in contributing to clinical outcome following SCI. In
future studies, it would be interesting to assess whether
differences in acute-phase response signalling in the different
phases of injury exist between individuals with varying injury
severities and/or who either do or do not show long-term
neurological improvements.
This study presents the first unbiased assessment of the blood
proteome in rodent models of SCI. A large number of proteins
have been identified which, with further study, may have the
potential to inform on the type and severity of injury from the
acute through to the chronic phase of SCI. Moreover, we have
identified biological mechanisms that are associated with these
protein changes, thus providing a better understanding of the
blood proteome changes that occur in response to SCI.
DATA AVAILABILITY
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